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Abstract: Chemerin, acting through its receptor ChemR23, is an adipokine associated with
inflammatory response, glucose and lipid metabolism and vascular function. Although this adipokine
has been associated with the development and progression of kidney disease, it is not clear whether
the chemerin/ChemR23 system plays a role in renal function in the context of diabetes. Therefore,
we sought to determine whether ChemR23 receptor blockade prevents the development and/or
progression of diabetic nephropathy and questioned the role of oxidative stress and Nrf2 in this
process. Renal redox state and function were assessed in non-diabetic lean db/m and diabetic obese
db/db mice treated with vehicle or CCX832 (ChemR23 antagonist). Renal reactive oxygen species
(ROS) production, which was increased in diabetic mice, was attenuated by CCX832. This was
associated with an increase in Nox 4 expression. Augmented protein oxidation in db/db mice was
not observed when mice were treated with CCX832. CCX832 also abrogated impaired Nrf2 nuclear
activity and associated downregulation in antioxidants expression in kidneys from db/db mice.
Our in vivo findings highlight the role of the redox signaling and Nrf2 system as renoprotective
players during chemerin receptor blockade in diabetic mice. The chemerin/ChemR23 system may be
an important target to limit renal dysfunction associated with obesity-related diabetes.
Keywords: chemerin; ChemR23; kidney; type 2 diabetes; oxidative stress
1. Introduction
Chemerin, also known as tazarotene-induced gene-2 protein or retinoic acid receptor responder
protein-2 (RARRES2), is a 16 kDa protein predominantly secreted by adipose tissue and skin [1,2].
It has been associated with inflammatory response, glucose and lipid metabolism [3] and vascular
function [4,5]. Chemerin is a ligand for the chemokine-like receptor 1 (CMKLR1; also called ChemR23),
a Gi protein-linked receptor mainly expressed by dendritic cells, macrophages, adipose tissue, vascular
smooth muscle and endothelial cells, in addition to the chemokine receptor like 2 (CCRL2) and
G-protein-coupled receptor 1 (GPR1) [6–8].
Int. J. Mol. Sci. 2018, 19, 2454; doi:10.3390/ijms19082454 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 2454 2 of 15
Chemerin gene expression is elevated in psoriasis [9], inflammatory diseases including ulcerative
colitis and Crohn’s disease [10], obesity [11–13], and a meta-analysis data linked elevated plasma levels
of chemerin to the metabolic syndrome (MetS) [14]. Pregnant women with preeclampsia also present
increased serum levels of chemerin, which is maintained six months after the pregnancy [15]. Enhanced
expression of chemerin in white adipose tissue, skeletal muscle, and liver has been reported in db/db
mice, an experimental model of obesity-related type 2 diabetes (T2D) where this adipokine exacerbates
glucose intolerance, lowers serum insulin levels, and decreases tissue glucose uptake [16,17].
High circulating levels of chemerin are also associated with progression of kidney dysfunction [18]
and chronic inflammation, insulin resistance, and disorders of glucose and lipid metabolism, which
are abnormalities commonly observed in chronic kidney disease (CKD) [19,20]. In patients with severe
renal damage, this adipokine is expressed in tubular epithelial cells and lymphatic endothelial vessels
and has been identified as a product of endothelial and proximal tubular epithelial cells. Additionally,
the chemerin/ChemR23 system recruits dendritic cells within the kidney and may play a role in renal
inflammation [21]. Moreover, it has been demonstrated that chemerin is associated with impaired
cardiovascular function [4,5], which may be an aggravating factor to the enhanced cardiovascular risk
in CKD.
Several studies have shown that oxidative stress is of major importance in the pathogenesis and
progression of renal and systemic diseases [22–25]. An imbalance in reactive oxygen species (ROS)
levels is an outcome of their dysregulated production and/or a deficient antioxidant function [26].
ROS are mainly produced by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (Nox),
which are an important source of superoxide anion (O2−) and hydrogen peroxide (H2O2) in the
cardiovascular system [27]. Even though multiple Nox homologues have already been identified,
Nox 4 is particularly important in renal pathobiology since is the most abundant Nox isoform in
the kidney [28], being considered the major source of ROS in renal cells and tissue in diabetes [29].
Diabetic mice commonly exhibit increased vascular and renal oxidative stress, and treatment with
antioxidant ameliorates renal disorders in these animals [30,31]. The nuclear erythroid-2 like factor-2
(Nrf2) transcription factor is the master regulator of the endogenous antioxidant defense system [32].
Chemerin, through Nox-derived ROS, stimulates mitogenic and pro-inflammatory signalling pathways
promoting vascular damage and remodelling [33].
Although chemerin has been associated with insulin resistance in cardiomyocytes and skeletal
muscle cells [34,35] and with kidney disease [18,19], the role of the chemerin/ChemR23 system in renal
function in the context of diabetes has not been fully elucidated. We previously showed that increased
plasma chemerin is associated with hyperglycemia in obese diabetic db/db mice [36]. Here we extend
those studies by exploring the effects of ChemR23 receptor blockade on renal redox homeostasis
during the early stages of nephropathy in diabetic db/db mice.
2. Results
2.1. Chemerin Receptor Blockade Decreases Kidney Mass and Creatinine Levels in db/db Mice
In db/db mice, which we previously phenotyped [37–40] we show that chemerin receptor
antagonism by CCX832 did not significantly alter increased kidney mass (Figure 1A), but it decreased
urinary creatinine levels (Figure 1B) and albuminuria (Figure 1C) in db/db diabetic mice, indicating
that CCX832 prevents renal dysfunction observed in db/db mice. No differences in these parameters
were observed between control db/m mice treated with vehicle or CCX832 (Figure 1A–C).
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Figure 1. ChemR23 antagonism decreases albuminuria and urinary creatinine levels in db/db mice. 
Kidney mass (A) urinary creatinine, (B) and albumin levels, (C) in vehicle-treated or CCX832-treated 
db/m and db/db mice. Kidney mass (g) was normalized by the tibia length (mm). Values represent 
the mean ± SEM (standard error deviation) of 5 to 8 experiments. * p < 0.05 vs. db/m, ∞ p < 0.05 vs. 
db/db vehicle. 
2.2. CCX832 Reduces Renal Oxidative Stress in db/db Mice 
Considering that chemerin increases ROS production [33], we investigated whether ChemR23 
antagonism attenuates renal ROS generation in db/db mice. Figure 2A,B demonstrate that kidneys 
from obese/diabetic (db/db) mice present increased ROS production in comparison to kidneys from 
vehicle- and CCX832-treated db/m mice (Figure 2A,B). Renal ROS generation in db/db mice was 
significantly attenuated by treatment with CCX832 (Figure 2A,B).  
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Figure 2. CCX832 reduces renal oxidative stress and Nox 4 expression in db/db mice. (A) 
Representative images and (B) quantitative analysis of 8-hydroxyguanosine (8-OHG)-positive nuclei 
in kidneys from vehicle or CCX832-treated db/m and db/db mice. Scale bar = 50 µm; 20X. (C) Renal 
H2O2 levels were measured by Amplex red assay. Amplex red values were normalized by protein 
content. (D) Gene expression of Nox 4 in kidneys was determined by real time PCR. The values were 
normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression. Results 
represent the mean ± SEM of 5 to 6 experiments. * p < 0.05 vs. db/m, ∞ p < 0.05 vs. db/db vehicle. 
Kidneys from db/db mice also exhibited increased H2O2 levels (Figure 2C), which were 
associated with increased Nox 4 mRNA expression (Figure 2D). Both outcomes were significantly 
decreased by ChemR23 antagonism (Figure 2C,D). No differences in H2O2 or Nox 4 mRNA levels 
were observed between db/m mice treated with vehicle or CCX832 (Figure 2A–D). No changes were 
observed in Nox 1 or Nox 2 expression (Supplemental Figure S1). Together, these data suggest that 
CCX832 ameliorates redox-sensitive processes in kidneys from db/db mice. 
  
Figure 2. CCX832 reduces renal oxidative stress and Nox 4 expression in db/db mice. (A) Representative
images and (B) quantitative analysis of 8-hydroxyguanosine (8-OHG)-positive nuclei in kidneys from
vehicle or CCX832-treated db/m and db/db mice. Scale bar = 50 µm; 20X. (C) Renal H2O2 levels were
measured by Amplex red assay. Amplex red values were normalized by protein content. (D) Gene
expression of Nox 4 in kidneys was determined by real time PCR. The values were normalized
by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression. Results represent the
mean ± SEM of 5 to 6 experiments. * p < 0.05 vs. db/m, ∞ p < 0.05 vs. db/db vehicle.
i from db/db mice also exhibited increased H2O2 levels (Figure 2C), which were associated
with ncreased Nox 4 mRNA expression (Figure 2D). Both outcomes were significantly decreased by
ChemR23 antagonism (Figure 2C,D). No differences in H2O2 or Nox 4 mRNA levels were obs rved
b tween db/m mic treated with vehicle or CCX832 (Figure 2A–D). No changes were observed in
Nox 1 or Nox 2 expression (Supplemental Figure S1). Tog ther, these data suggest that CCX832
ameliorates redox-sensitive processes in kidneys from db/db mice.
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2.3. CCX832 Reduces Protein Oxidation in Kidneys from db/db Mice
Considering that (1) ROS Considering generation modulates many vascular processes via
oxidation of proteins; (2) there is increased ROS production in kidneys from db/db mice; and (3) protein
tyrosine phosphatases (PTPs) are particularly sensitive to oxidative stress and vulnerable to oxidation,
which results in the inhibition of the enzymes, we addressed whether CCX832 interferes with renal
PTP oxidation. In kidneys from db/db mice, PTP oxidation (Figure 3A) as well as peroxiredoxin
oxidation (Prdx-SO3) and carbonylation, a type of irreversible oxidation induced by oxidative stress
(Figure 3B,C, respectively) were significantly increased. Increased oxidation and carbonylation of
proteins was not observed when the animals were treated with CCX832 (Figure 3A–C), showing that
ChemR23 blockade plays a protective role in renal protein oxidation in db/db mice.
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Figure 3. ChemR23 antagonism decreases renal carbonylation, protein-tyrosine phosphatases (PTPs)
and Prdx oxidation in db/db mice. The experiments were performed in kidneys from vehicle or
CCX832-treated db/m and db/db mice. (A) PTPs oxidation was assessed by western blot. (B) Protein
carbonylation was assessed by OxyBlot. (C) Prdx-SO3 oxidation was assessed by western blot.
The values were normalized by α-tubulin or β-actin expression. Bars represent the mean ± SEM
of 5 to 8 experiments. * p < 0.05 vs. db/m, ∞ p < 0.05 vs. db/db vehicle.
Int. J. Mol. Sci. 2018, 19, 2454 6 of 15
2.4. ChemR23 Antagonism Restores the Function of Renal Nrf2 Antioxidant System in db/m Mice
To investigate the effects of CCX832 on Nrf2-regulated antioxidant enzymes in kidneys from
db/db mice, we assessed Nrf2 activity and antioxidant enzymes mRNA expression. In addition to
its effects on ROS generation and protein oxidation, CCX832 also restored the impaired Nrf2 nuclear
translocation (Figure 4A) observed in kidneys from db/db mice. Furthermore, CCX832-treated db/db
mice did not exhibit decreased mRNA levels of catalase, superoxide dismutase-1 (SOD1), thioredoxin-1
(Thrx1) or peroxiredoxin-1 (Prdx1) as observed in kidneys from obese/diabetic mice (Figure 4B–E,
respectively). CCX832 did not change Nrf2 translocation or antioxidant enzymes gene expression in
db/m mice. These data suggest that ChemR23 antagonism improves renal Nrf2 antioxidant system in
db/db mice.
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Figure 4. ChemR23 antagonism attenuates impaired Nrf2 nuclear translocation and increases
antioxidant enzymes expression in kidneys from db/db mice. (A) Nuclear accumulation of Nrf2
was determined by ELISA in nuclear extract of kidneys from vehicle and CCX832-treated db/m and
db/db mice. (B–E) mRNA expression of genes regulated by Nrf2 was determined by real time PCR.
The values were normalized by total protein levels (A) or by GAPDH mRNA expression (B–E). Results
represent the mean ± SEM of 5 to 8 experiments. * p < 0.05 vs. db/m, ∞ p < 0.05 vs. db/db vehicle.
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In order to investigate the renal inflammatory profile of db/db mice, gene expression of
two pro-inflammatory markers were addressed. Kidneys from db/db mice presented increased
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) mRNA expression, which was attenuated
by CCX832 (Figure 5A,B). Despite the high oxidative state and increased expression of inflammatory
markers observed, no histological alterations were found at this stage in kidneys from db/db mice
(Figure 5C,D), which indicates that the redox changes and inflammatory renal profile seen in db/db
mice precede any renal structural abnormalities associated with the diabetic condition.
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3. Discussion
Our knowledge on the chemerin/ChemR23 axis in cardiovascular function has rapidly progressed.
Growing evidence indicates a role for chemerin in kidney disease. However, implications of chemerin
in diabetic nephropathy are unclear. Here we advance the field by demonstrating an important role for
chemerin in renal oxidative stress and renal dysfunction in a model of diabetes. Particularly, we show
that chemerin receptor blockade by CCX832 reduces renal ROS production and protein oxidation.
Potential mechanisms underlying the renal effects of chemerin involve upregulation of Noxs and
downregulation of Nrf2-regulated anti-oxidant genes. These phenomena, observed in the absence
of renal structural dysfunction or fibrosis, highlight that chemerin-induced renal alterations precede
renal damage in this animal model.
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Obesity and diabetes are major co-morbidities associated with cardiovascular complications,
nephropathy and end stage-renal disease. Within the context of nephropathy, adipokines, such as leptin,
resistin, visfatin and chemerin, have their serum levels markedly correlated to the disorders observed
in renal diseases [41]. In the last few years, several reports have investigated the circulating chemerin
levels and their potential significance to renal diseases development and progression. The interplay
between chemerin and renal function was first demonstrated in chronic hemodialysis (HD) patients,
in which serum chemerin levels were more than two-fold higher [42]. Later findings showed that serum
creatinine is also associated with serum chemerin levels in type 2 diabetes patients [43]. Corroborating
this, major findings in the present study demonstrate that ChemR23 blockade reduces albuminuria as
well as urinary creatinine levels in diabetic obese mice.
Vascular and renal oxidative stress have been consistently demonstrated in experimental
models [44–46] and patients with diabetes [47]. High glucose and other pro-diabetic conditions
are known to increase ROS production via activation of Noxs [47,48]. In renal pathobiology Nox 4 is
particularly important due to its abundance in the kidney [28] and it is a major source of ROS in renal
cells and tissues during diabetes [49]. In line with these findings, we have demonstrated in this study
that the db/db diabetic obese mouse model presents increased ROS generation and Nox 4 expression
in kidneys, which were reversed by chemerin receptor antagonism. It is of importance to note that
our group already demonstrated that chemerin impairs vascular function and signaling through
Nox activation in human cells [33]. Although CCX832 has been previously described as a ChemR23
antagonist and a blocker of chemerin signals [4,50–53], we have not provided direct evidence that
CCX832 disrupts chemerin/ChemR23 signaling, which represents a limitation of the present study.
Renal functional and morphological alterations during diabetes are ameliorated by antioxidant
treatment [54,55]. Recent clinical studies evidenced a significant improvement in renal function in
patients with advanced CKD and T2D treated with an oral antioxidant, bardoxolone [56]. Renal
oxidative stress observed in db/db mice in this study was associated with decreased activity of
Nrf2 as evidenced by its decreased nuclear translocation. Loss of Nrf2 activity was associated with
downregulated expression of anti-oxidant genes, such as catalase, SOD1, thrx1 and prdx, which likely
dampens the antioxidant defense in the kidneys from these animals. Once again, a key role of the
chemerin/chemR23 system to renal oxidative stress in db/db mice was evidenced, since the blockade
of ChemR23 reversed such deleterious responses.
ROS modulate several cellular responses via protein oxidation, such as inhibition of PTPs via
oxidation of its cysteine residues [57]. In this study, the potential of irreversible oxidation was used to
address a potential effect of chemerin in the regulation of PTP function. ChemR23 antagonism reduced
the increased PTPs oxidation observed in kidneys from db/db mice, an effect concomitantly linked to
decreased ROS generation in these tissues. The inactivation of PTPs in kidney may increase/augment
phosphorylation of various signaling proteins, which can contribute to diabetes-associated renal
dysfunction. Additionally, kidneys from db/db mice treated with CCX832 present a reduction in
protein carbonylation, a biomarker for oxidative stress–induced irreversible damage that leads to
loss of protein function [58]. Peroxiredoxin was also targeted by chemerin. Peroxiredoxin, when
hyperoxidized, becomes inactivated [59], which makes the kidney vulnerable to damage associated
with oxidative stress. These proteins may represent targets of the chemerin/ChemR23 system and
may underlie their association with impaired renal function in diabetic obese mice.
Despite the increased renal mass, albuminuria, increased urinary creatinine levels and renal
oxidative stress observed in db/db mice, no glomerular lesions, mesangial matrix expansion or
alterations in fibrotic markers expression were observed in the kidneys of db/db mice. These data
indicate that renal injury and functional changes observed in our study precede the structural damage
in this animal model. A recent study showed that 10 weeks-old male db/db mice present a significant
increase in urinary albumin and kidney weight although only a mild accumulation of mesangial matrix
and no remarkable changes in the tubulointerstitium were found [60]. Cohen et al. [61] observed no
changes in the mesangial compartment of the db/db mouse at 8 weeks of age although a twofold
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increase in mesangial matrix was found when the animals reached 12 weeks. Interestingly and
corroborating the suggestion that adipokines play an important role in renal dysfunction during
diabetes, a very recent study has shown that an orally administered synthetic adiponectin receptor
agonist, which is an adipokine with protective effects during diabetes and metabolic syndrome
through its anti-inflammatory, antifibrotic, and antioxidant effects, reverses diabetic nephropathy in
16 weeks-old male db/db mice [62].
4. Materials and Methods
4.1. Animals
All experimental protocols were performed in accordance with the Ethical Principles in Animal
Experimentation adopted by the National Council for Animal Experimentation Control (CONCEA)
and were approved by the Ethics Committee on Animal Use (CEUA; protocol 062/2012—25 June 2012)
of the University of Sao Paulo, Ribeirao Preto, Brazil and by the West of Scotland Research Ethics
Service (70/9021). Ten to twelve weeks-old male C57BL/6J, lean non-diabetic db/m and obese diabetic
db/db mice were housed in individually cages in a room with controlled humidity and temperature
(22–24 ◦C), and light/dark cycles of 12 h. Animals had free access to food and tap water. Mice were
treated with vehicle (PEG400/cremophor) or CCX832 (a gift from ChemoCentryx, Inc., Mountain View,
CA, USA), a ChemR23 antagonist (75 mg/kg/day, for 3 weeks, by oral gavage). Previous radiolabeled
binding studies revealed that CCX832 binds to human, mouse and rat ChemR23 receptors with a
low nanomolar affinity [4,51]. CCX832 was specially formulated by ChemoCentryx for the in vitro
studies and for the daily oral administration in the in vivo studies. Body weight was measured weekly
from the beginning of the treatment. Animals were separated into 4 groups: db/m + vehicle, db/m +
CCX832, db/db + vehicle and db/db + CCX832. In initial experiments, two additional groups were
included: db/m and db/db mice without any treatment for the same three week-period, or untreated
db/m and db/db mice, respectively. Since no difference was observed between untreated and vehicle
groups, the remaining protocols were performed in animals treated with vehicle and CCX832. At the
end of the treatment, urine and kidneys were collected. The kidneys were weighed, and the kidney
mass values were normalized by the respective tibia length. To respect the principles of the 3Rs
(replacement, reduction and refinement) in research, we examined mice that we have previously
characterized [63].
4.2. Assessment of Urinary Creatinine and Albumin Levels
Spot urine samples were collected immediately before death. Creatinine and albumin urine levels
in vehicle- or CCX832-treated db/m and db/db mice were determined by an enzymatic reaction
according to instructions from the manufacturer (Catalogue #127 and #19, respectively—Labtest®,
Santa Barbara d’Oeste, Brazil).
4.3. Immunoblotting
Western blotting was used to evaluate protein expression in kidneys from db/m and
db/db mice treated with vehicle or CCX832. Briefly, tissues were homogenized in lysis
buffer [(in mmol/L) sodium pyrophosphate 50, sodium Fluoride (NaF) 50, sodium chloride
(NaCl) 5, ethylenediaminetetraacetic acid (EDTA) 5, ethylene glycol tetraacetic acid (EGTA) 5,
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 10, Sodium orthovanadate (Na3VO4)
2, phenylmethylsulfonyl fluoride (PMSF) 50, Triton 100 0.5%, and leupeptin/aprotinin/pepstatin
(1 mg/mL)] and then sonicated for 5 s. Proteins extracted from each lysate were separated by
electrophoresis on 8 to 12% sodium dodecyl sulfate (SDS) polyacrylamide gel and transferred to a
nitrocellulose membrane for Western blotting with specified antibodies. Nonspecific binding sites
were blocked with 5% milk in Tris-buffered saline solution with Tween for 1 h at room temperature.
After incubation with secondary antibodies, signals were revealed with chemiluminescence, visualized
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by autoradiography, and quantified densitometrically with the open-source software ImageJ (available
online: http://imagej.nih.gov/ij/). Results were normalized to β-actin or α-tubulin. Antibodies used
were as follows: Prdx-SO3 (Abcam ab16830; 1:2000, Cambridge, MA, USA), OxyPTP (R&D Systems
MAB2844; 1 µg/mL, Minneapolis, MN, USA), OxyBlot (Millipore S7150; 1:1000, Burlington, MA, USA),
anti-α-tubulin and anti-β-actin are from Sigma (1:10,000, St. Louis, MO, USA).
4.4. Immunofluorescence
8-Hydroxyguanosine (8-OHG) is a modified guanosine that occurs in DNA/RNA due to attack
by hydroxyl radicals that are formed as by products and intermediates of aerobic metabolism and
during oxidative stress [64]. 8-hydroxyguanosine (8-OHG) immunohistochemistry has been widely
used as a sensitive, stable and integral biomarker of oxidative stress-induced DNA and RNA damage.
Paraffin sections of kidney (3 µm) were deparaffinized in xylene, rehydrated through graded
ethanol, and washed in water. All sections were incubated in EDTA (pH 8) and boiled for 15 min
(min) at 95 ◦C for antigen unmasking. Slides were cooled to room temperature, permeabilized in
0.5% Triton X-100 in phosphate-buffered saline (PBS) for 5 min, and blocked with 10% donkey serum,
1% bovine serum albumin (BSA) in 1X Tris-buffered saline and Tween 20 (TBS-T) for 1 h at room
temperature in a humidified chamber. For 8-OHG immunostaining, slides were incubated overnight
with anti-8-OHG goat polyclonal antibody (Abcam ab10802, 1:200 diluted in 5% donkey serum, 0.02%
BSA, 0.0025% Tween-20 in 1X TBS solution) in a humidified chamber. Alexa-fluor-488-conjugated
donkey anti-goat secondary antibody (Molecular probes, A-11055, 1:300 dilution in 5% donkey, 0.02%
BSA, 0.0025% Tween-20 in 1X TBS solution, St. Louis, MO, USA) was used after primary antibody
incubation for 1 h at room temperature in the dark. The slides were treated with 0.1% Sudan Black
B (Sigma Aldrich, Cat. Number: 199664, St. Louis, MO, USA) in methanol for 10 min to remove
lipofuscin-mediated autofluorescence. Nuclei were counterstained with 4-6-diamidino-2-phenylindole
(DAPI at 100 µg/mL) for 10 min. Sections were mounted with a coverslip using ProLong Gold
anti-fade mounting media containing DAPI (Molecular probes, P-36931) in the dark. Fluorescence
images were captured using Axiovert 200M microscope with a laser-scanning module LSM 510 (Carl
Zeiss AG, Heidelberg, Germany). For negative controls, goat IgG-matched isotype controls were
used (Santa Cruz, sc-2028, Dallas, TX, USA). The fluorescence intensity, which indicates DNA damage
induced by oxidative stress, in the endothelium and SMC layers was measured.
4.5. Amplex Red Assay
Hydrogen peroxide (H2O2) levels were assessed in kidney according to the manufacturer’s
instruction using the horseradish peroxidase-linked Amplex Red fluorescence assay (Life Technologies,
Carlsbad, CA, USA).
4.6. Real Time PCR
Quantitative real-time PCR (Applied Biosystems, Foster City, CA, USA) was used to analyze
mRNA expression. Briefly, total RNA was extracted from kidneys using TRIzol (Qiagen, Manchester,
UK), treated with RNase-free DNAse I, and 2 µg of RNA were reverse transcribed in a reaction
containing 100 µg/mL oligo-dT, 10 mmol/L of 2′-deoxynucleoside 5′-triphosphate, 5X First-Strand
buffer, and 2 µL of 200-U reverse transcriptase. For real-time PCR amplification, 3 µL of each reverse
transcription product were diluted in a reaction buffer containing 5 µL of SYBR Green PCR master
mix and 300 nmol/L of primers in a final volume of 10 µL per sample. The reaction conditions
consisted of 2 steps at 50 ◦C for 2 min and 95 ◦C for 2 min, followed by 40 cycles of 3 steps, 15 s
denaturation at 95 ◦C, 60 s annealing at 60 ◦C, and 15 s at 72 ◦C. The relative mRNA expressions (target
gene/Gapdh housekeeping gene) were calculated by ∆∆Ct method. The following mice primers were
used in this study: Nox 1 (FW: TCCCTTTGCTTCCTTCTTGA; RW: CCAGCCAGTGAGGAAGAGTC),
Nox 2 (FW: CGCCCTTTGCCTCCATTCTC; RW: CCTTTCCTGCATCTGGGTCTCC), Nox 4 (FW:
CCAGAATGAGGATCCCAGAA; RW: AGCAGCAGCAGCATG); Catalase (FW: ACATGGTCTGGG
Int. J. Mol. Sci. 2018, 19, 2454 11 of 15
ACTTCTGG; RW: CAAGTTTTTGATGCCCTGGT), SOD1 (FW: GAGACCTGGGCAATGTGACT; RW:
TTGTTTCTCATGGACCACCA), THRX1 (FW: TGTCGTGGTGGACTTCTCTG; RW: TCAAGGAA
CACCACATTGGA) and PRDX1 (FW: CACCCAAGAAACAAGGAGGA; RW: AAAAAGGCCCC
TGAAAGAGA).
4.7. Protein Oxidation
Levels of protein-tyrosine phosphatases (PTPs) and peroxiredoxin oxidation were evaluated by
Western blot and carbonylation by OxyBlot assay (Millipore S7150).
The OxyBlot assay performed in this study detects carbonyl groups introduced into proteins’ side
chains by a site-specific mechanism. All bands in the membranes were quantified considering that
many proteins undergo carbonylation and that the antibody is not specific for a particular PTP.
4.8. Nrf2 Activity
To determine nuclear accumulation of Nrf2, kidney nuclear lysates were separated using the
Active Motif nuclear extract kit (Active Motif, Carlsbad, CA, USA) following the manufacturer’s
protocol. Briefly, lysates were resuspended in 1X hypotonic buffer and centrifuged for 30 s at 14,000× g
in a microcentrifuge pre-cooled at 4 ◦C. Nuclear pellets were resuspended in lysis buffer provided
by the manufacturer. The suspension was incubated for 30 min on ice on a rocking platform set
at 150 rpm and then centrifuged for 10 min at 14,000× g. The supernatant was transferred to a
prechilled microcentrifuge tube. TransAM Nrf2 ELISA kit (Active Motif) was used to measure nuclear
accumulation of Nrf2 at a wavelength of 450 nm.
4.9. Histopathology
Kidneys were removed and weighed. The kidney weight (g) was corrected by the length of the
tibia (mm). Kidneys from control and treated animals were fixed in 4% neutral buffered formalin
solution, rinsed with 70% ethanol, dehydrated through a graded alcohol series, and embedded
in paraffin. Sections of 3 µm of renal tissue from these animals were stained methenamine-silver
nitrate for histological analysis. For each stained section, the glomerular mesangial expansion and
tubulointerstitial injury were evaluated using scores on a scale of 0 to 4 that reflected changes in the
extent (0 = 5–25%, 1 = 25–50%, 3 = 50–75%, and 4 = 75–100%) of renal injury/ renal abnormalities.
The Zeiss Axio microscope with AxioCam MRC (Program AxioVision Release 4.8.2. [06-2010],
Oberkochen, Germany) was used for images acquisition.
4.10. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 3.0 (GraphPad Software Inc., San Diego,
CA, USA). Data are presented as means ± standard error of the mean (SEM). Groups were compared
using student’s t test or one-way analysis of variance (ANOVA). Bonferroni or Tukey’s post-test were
used as appropriate. Results of statistical tests with p < 0.05 were considered as significant.
5. Conclusions
In conclusion, our data suggest that chemerin plays a role in renal damage in diabetic mice through
ROS- and oxidation-dependent mechanisms. CCX832 plays a renoprotective role by decreasing
oxidative status during the early stages of diabetes, when structural alterations are not observed.
These findings advance our understanding on potential pathways modulated by chemerin/ChemR23
axis, and their role in diabetic nephropathy. In this context, CCX832 may be a novel promising
candidate to ameliorate diabetes-associated nephropathy.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/8/
2454/s1.
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H2O2 hydrogen peroxide
O2− superoxide anion
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